The EPO published patent application EP3985104A1 on March 25, 2026, disclosing a method for producing renal interstitial cells. The applicants are Kyoto University and Takeda Pharmaceutical Company Limited, with inventors Makoto Ikeya and Daisuke Kamiya. The invention is classified under IPC C12N 5/077 (stem cells) and related categories including C12N 5/071, C12N 5/0797, and A61K 35/22.

This document is a patent publication notice with no regulatory compliance requirements for external parties. Patent applications do not impose obligations on competitors or the public. There are no compliance deadlines, required actions, or penalties associated with this publication. Companies in the pharmaceutical or biotechnology sector conducting research in kidney disease or regenerative medicine should be aware of this patent filing as prior art.